Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2026-08-17 17:34:05 ET · period of report 2026-08-13 · accession 0001193125-26-354313 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-08-17 17:34 | 2026-08-13+ | FDMT | Bizily Scott | CLO | M - OptEx | $4.14 | +3,270 | 10.3K | +47% | +$13.5K |
| DMT | 2026-08-17 17:34 | 2026-08-13+ | FDMT | Bizily Scott | CLO | S - Sale+OE | $12.10 | -3,270 | 8,617 | -28% | -$39.6K |
| DMT | 2026-08-17 17:34 | 2026-08-13+ | FDMT | Bizily Scott | CLO | M - OptEx | $0.00 | -3,270 | 59.7K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-13 | M | A | 1,635 | $4.14 | 10,252 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-13 | S | D | 1,635 | $12.00 | 8,617 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| 3 | Common | Common Stock | 2026-08-17 | M | A | 1,635 | $4.14 | 10,252 | D | — | — | |
| 4 | Common | Common Stock | 2026-08-17 | S | D | 1,635 | $12.20 | 8,617 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-08-13 | M | D | 1,635 | $0.00 | 61,336 | D | $4.14 · — to 2035-03-05 | 1,635 Common Stock | (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-08-17 | M | D | 1,635 | $0.00 | 59,701 | D | $4.14 · — to 2035-03-05 | 1,635 Common Stock | (F2) The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |